Oxybutynin for diagnosis of infravesical obstruction in boys with urinary incontinence.
OBJECTIVE
To investigate whether good suppression of symptoms during anticholinergic therapy in boys with urinary urge incontinence is correlated with anatomic infravesical obstruction.


METHODS
In a prospective study, 65 boys with urge incontinence were treated temporarily with anticholinergics. The effect of therapy was assessed, and a full video-urodynamic evaluation was performed. When obstruction could not be excluded urodynamically, urethrocystoscopy was done to assess the level and severity of obstruction, followed by endoscopic treatment. The effect of oxybutynin on incontinence was compared with the presence or absence of obstruction.


RESULTS
In 49 of 65 boys aged 4 to 14 years with daytime urge incontinence, infravesical obstruction was found. Of the 49 boys, 38 (76%) had a good response to anticholinergic therapy. Of the 16 boys without infravesical obstruction, 12 (75%) did not improve with anticholinergic therapy. When anticholinergic therapy was used as a diagnostic test for infravesical obstruction, we found a positive predictive value and negative predictive value of 90% (95% confidence interval 74% to 96%) and 52% (95% confidence interval 31% to 73%), respectively.


CONCLUSIONS
The effect of anticholinergic therapy on urge incontinence can be used as a diagnostic test to differentiate between anatomic infravesical obstruction and other causes of incontinence in boys.
de Kort
Laetitia M O
LM
Department of Pediatric Urology, University Medical Center Utrecht, Utrecht, The Netherlands.
Klijn
Aart J
AJ
Dik
Pieter
P
Uiterwaal
Cuno S P M
CS
de Jong
Tom P V M
TP
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D008333:Mandelic Acids / Q000627:therapeutic use; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D011237:Predictive Value of Tests; D011446:Prospective Studies; D014521:Urethra / Q000002:abnormalities; D014524:Urethral Obstruction / Q000150:complications / Q000175:diagnosis*; D014549:Urinary Incontinence / Q000188:drug therapy / Q000209:etiology*; D014563:Urodynamics
D008333:Mandelic Acids; D018727:Muscarinic Antagonists; C005419:oxybutynin